Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial (IVN-CAT-001B)

This study has been completed.
ImVision GmbH, Hannover
Information provided by:
University of Zurich Identifier:
First received: July 18, 2008
Last updated: February 10, 2010
Last verified: February 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2010
  Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):